{
  "id": "mhgap#risk_safety_80b26d69",
  "content": "y Lithium, sodium valproate and carbamazepine\nsupervision. If laboratory examinations are not\nrequire regular blood monitoring, which also\navailable or feasible, lithium should be avoided and\nadds costs.\nother mood stabilizers or antipsychotics should\ny Lithium carbonate, sodium valproate (valproic\nbe considered. Do not prescribe lithium where the\nacid), carbamazepine and quetiapine (therapeutic\nlithium supply may be frequently interrupted due to\nalternatives: aripiprazole, olanzapine, paliperidone)\nincreased risk of relapse. Clinicians should conduct\nare available in the WHO EML (13).\n99\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY9. In adults presenting with a depressive episode in bipolar disorder,\nare medicines with antidepressant effects (adjunct to maintenance\ntreatment) effective and safe?\nRecommendation (update): Fluoxetine, olanzapine, quetiapine, valproic acid (sodium valproate) or\nvenlafaxine should be considered for adults with bipolar depression. If\nfluoxetine or venlafaxine are chosen, they should be co-administered with\na mood stabilizer (namely quetiapine, olanzapine, carbamazepine, valproic\nacid [sodium valproate], lithium).\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification Remarks\ny Data were extracted from an NMA: Yildiz et al., 2023 y Please refer to recommendation PSY8 to find",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety y Lithium, sodium valproate and carbamazepine\nsupervision. If laboratory examinations are not\nrequire regular blood monitoring, which also\navailable or feasible, lithium should be avoided and\nadds costs.\nother mood stabilizers or antipsychotics should\ny Lithium carbonate, sodium valproate (valproic\nbe considered. Do not prescribe lithium where the\nacid), carbamazepine and quetiapine (therapeutic\nlithium supply may be frequently interrupted due to\nalternatives: aripiprazole, olanzapine, paliperidone)\nincreased risk of relapse. Clinicians should conduct\nare available in the WHO EML (13).\n99\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nPSY9. In adults presenting with a depressive episode in bipolar disorder,\nare medicines with antidepressant effects (adjunct to maintenance\ntreatment) effective and safe?\nRecommendation (update): Fluoxetine, olanzapine, quetiapine, valproic acid (sodium valproate) or\nvenlafaxine should be considered for adults with bipolar depression. If\nfluoxetine or venlafaxine are chosen, they should be co-administered with\na mood stabilizer (namely quetiapine, olanzapine, carbamazepine, valproic\nacid [sodium valproate], lithium).\nStrength of recommendation: Conditional\nCertainty of evidence: Very low\nJustification Remarks\ny Data were extracted from an NMA: Yildiz et al., 2023 y Please refer to recommendation PSY8 to find Y lithium, sodium valproate and carbamazepine\nsupervision. if laboratory examinations are not\nrequire regular blood monitoring, which also\navailable or feasible, lithium should be avoided and\nadds costs."
}